FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102534146> ?p ?o ?g. }

• W2102534146 endingPage "1080" @default.
• W2102534146 startingPage "1072" @default.
• W2102534146 abstract "Purpose: To give an update on the long-term outcome of an intensified protocol of combined radiochemotherapy (RCT) with 5-fluorouracil (5-FU) and cisplatin after initial transurethral resection of bladder tumor (TURBT) with selective organ preservation in bladder cancer. Methods and Materials: One hundred twelve patients with muscle-invading or high-risk T1 (G3, associated Tis, multifocality, diameter >5 cm) bladder cancer were enrolled in a protocol of TURBT followed by concurrent cisplatin (20 mg/m2/day as 30-min infusion) and 5-FU (600 mg/m2/day as 120-h continuous infusion), administered on Days 1–5 and 29–33 of radiotherapy. Response to treatment was evaluated by restaging TURBT 4–6 weeks after RCT. In case of invasive residual tumor or recurrence, salvage cystectomy was recommended. Results: Ninety-nine patients (88.4%) had no detectable tumor at restaging TURBT; 71 patients (72%) have been continuously free from local recurrence or distant metastasis. Superficial relapse occurred in 13 patients and muscle-invasive recurrence in 11 patients. Overall and cause-specific survival rates for all patients were 74% and 82% at 5 years, respectively. Of all surviving patients, 82% maintained their own bladder, 79% of whom were delighted or pleased with their urinary condition. Hematologic Grade 3/4 toxicity occurred in 23%/6% and Grade 3 diarrhea in 21% of patients. One patient required salvage cystectomy due to a shrinking bladder. Conclusion: Concurrent RCT with 5-FU/cisplatin has been associated with acceptable acute and long-term toxicity. Overall and cause-specific survival rates are encouraging. More than 80% of patients preserved their well-functioning bladder. Purpose: To give an update on the long-term outcome of an intensified protocol of combined radiochemotherapy (RCT) with 5-fluorouracil (5-FU) and cisplatin after initial transurethral resection of bladder tumor (TURBT) with selective organ preservation in bladder cancer. Methods and Materials: One hundred twelve patients with muscle-invading or high-risk T1 (G3, associated Tis, multifocality, diameter >5 cm) bladder cancer were enrolled in a protocol of TURBT followed by concurrent cisplatin (20 mg/m2/day as 30-min infusion) and 5-FU (600 mg/m2/day as 120-h continuous infusion), administered on Days 1–5 and 29–33 of radiotherapy. Response to treatment was evaluated by restaging TURBT 4–6 weeks after RCT. In case of invasive residual tumor or recurrence, salvage cystectomy was recommended. Results: Ninety-nine patients (88.4%) had no detectable tumor at restaging TURBT; 71 patients (72%) have been continuously free from local recurrence or distant metastasis. Superficial relapse occurred in 13 patients and muscle-invasive recurrence in 11 patients. Overall and cause-specific survival rates for all patients were 74% and 82% at 5 years, respectively. Of all surviving patients, 82% maintained their own bladder, 79% of whom were delighted or pleased with their urinary condition. Hematologic Grade 3/4 toxicity occurred in 23%/6% and Grade 3 diarrhea in 21% of patients. One patient required salvage cystectomy due to a shrinking bladder. Conclusion: Concurrent RCT with 5-FU/cisplatin has been associated with acceptable acute and long-term toxicity. Overall and cause-specific survival rates are encouraging. More than 80% of patients preserved their well-functioning bladder." @default.
• W2102534146 created "2016-06-24" @default.
• W2102534146 creator A5014763341 @default.
• W2102534146 creator A5020511633 @default.
• W2102534146 creator A5021167966 @default.
• W2102534146 creator A5030506578 @default.
• W2102534146 creator A5032663816 @default.
• W2102534146 creator A5074558569 @default.
• W2102534146 creator A5085027181 @default.
• W2102534146 date "2007-07-01" @default.
• W2102534146 modified "2023-10-06" @default.
• W2102534146 title "Radiochemotherapy With Cisplatin and 5-Fluorouracil After Transurethral Surgery in Patients With Bladder Cancer" @default.
• W2102534146 cites W1487698677 @default.
• W2102534146 cites W1786366031 @default.
• W2102534146 cites W1932620090 @default.
• W2102534146 cites W1952252771 @default.
• W2102534146 cites W1981696904 @default.
• W2102534146 cites W1983648619 @default.
• W2102534146 cites W2012054910 @default.
• W2102534146 cites W2018009626 @default.
• W2102534146 cites W2037305184 @default.
• W2102534146 cites W2047193631 @default.
• W2102534146 cites W2054282253 @default.
• W2102534146 cites W2074386077 @default.
• W2102534146 cites W2084800358 @default.
• W2102534146 cites W2089437147 @default.
• W2102534146 cites W2103492268 @default.
• W2102534146 cites W2105407988 @default.
• W2102534146 cites W2135108459 @default.
• W2102534146 cites W2140970165 @default.
• W2102534146 cites W2993539218 @default.
• W2102534146 cites W2003797088 @default.
• W2102534146 doi "https://doi.org/10.1016/j.ijrobp.2007.01.054" @default.
• W2102534146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17467193" @default.
• W2102534146 hasPublicationYear "2007" @default.
• W2102534146 type Work @default.
• W2102534146 sameAs 2102534146 @default.
• W2102534146 citedByCount "89" @default.
• W2102534146 countsByYear W21025341462012 @default.
• W2102534146 countsByYear W21025341462013 @default.
• W2102534146 countsByYear W21025341462014 @default.
• W2102534146 countsByYear W21025341462015 @default.
• W2102534146 countsByYear W21025341462016 @default.
• W2102534146 countsByYear W21025341462017 @default.
• W2102534146 countsByYear W21025341462018 @default.
• W2102534146 countsByYear W21025341462019 @default.
• W2102534146 countsByYear W21025341462020 @default.
• W2102534146 countsByYear W21025341462021 @default.
• W2102534146 countsByYear W21025341462022 @default.
• W2102534146 countsByYear W21025341462023 @default.
• W2102534146 crossrefType "journal-article" @default.
• W2102534146 hasAuthorship W2102534146A5014763341 @default.
• W2102534146 hasAuthorship W2102534146A5020511633 @default.
• W2102534146 hasAuthorship W2102534146A5021167966 @default.
• W2102534146 hasAuthorship W2102534146A5030506578 @default.
• W2102534146 hasAuthorship W2102534146A5032663816 @default.
• W2102534146 hasAuthorship W2102534146A5074558569 @default.
• W2102534146 hasAuthorship W2102534146A5085027181 @default.
• W2102534146 hasConcept C121608353 @default.
• W2102534146 hasConcept C126322002 @default.
• W2102534146 hasConcept C126894567 @default.
• W2102534146 hasConcept C141071460 @default.
• W2102534146 hasConcept C2775910329 @default.
• W2102534146 hasConcept C2776694085 @default.
• W2102534146 hasConcept C2778239845 @default.
• W2102534146 hasConcept C2779013556 @default.
• W2102534146 hasConcept C2779762690 @default.
• W2102534146 hasConcept C2780352672 @default.
• W2102534146 hasConcept C2780456651 @default.
• W2102534146 hasConcept C29730261 @default.
• W2102534146 hasConcept C509974204 @default.
• W2102534146 hasConcept C71924100 @default.
• W2102534146 hasConcept C77411442 @default.
• W2102534146 hasConceptScore W2102534146C121608353 @default.
• W2102534146 hasConceptScore W2102534146C126322002 @default.
• W2102534146 hasConceptScore W2102534146C126894567 @default.
• W2102534146 hasConceptScore W2102534146C141071460 @default.
• W2102534146 hasConceptScore W2102534146C2775910329 @default.
• W2102534146 hasConceptScore W2102534146C2776694085 @default.
• W2102534146 hasConceptScore W2102534146C2778239845 @default.
• W2102534146 hasConceptScore W2102534146C2779013556 @default.
• W2102534146 hasConceptScore W2102534146C2779762690 @default.
• W2102534146 hasConceptScore W2102534146C2780352672 @default.
• W2102534146 hasConceptScore W2102534146C2780456651 @default.
• W2102534146 hasConceptScore W2102534146C29730261 @default.
• W2102534146 hasConceptScore W2102534146C509974204 @default.
• W2102534146 hasConceptScore W2102534146C71924100 @default.
• W2102534146 hasConceptScore W2102534146C77411442 @default.
• W2102534146 hasIssue "4" @default.
• W2102534146 hasLocation W21025341461 @default.
• W2102534146 hasLocation W21025341462 @default.
• W2102534146 hasOpenAccess W2102534146 @default.
• W2102534146 hasPrimaryLocation W21025341461 @default.
• W2102534146 hasRelatedWork W2012557700 @default.
• W2102534146 hasRelatedWork W2016339089 @default.
• W2102534146 hasRelatedWork W2022837219 @default.
• W2102534146 hasRelatedWork W2031494910 @default.
• W2102534146 hasRelatedWork W2038776230 @default.

• next